Molecular Templates, Inc. (MTEM)
NASDAQ: MTEM · Real-Time Price · USD
0.160
-0.193 (-54.67%)
At close: Dec 20, 2024, 4:00 PM
0.150
-0.010 (-6.31%)
After-hours: Dec 20, 2024, 7:57 PM EST
Molecular Templates Revenue
Molecular Templates had revenue of $572.00K in the quarter ending June 30, 2024, a decrease of -91.67%. This brings the company's revenue in the last twelve months to $25.47M, down -49.41% year-over-year. In the year 2023, Molecular Templates had annual revenue of $57.31M with 190.10% growth.
Revenue (ttm)
$25.47M
Revenue Growth
-49.41%
P/S Ratio
0.04
Revenue / Employee
$410,806
Employees
62
Market Cap
1.05M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Scorpius Holdings | 10.04M |
Avinger | 7.26M |
China SXT Pharmaceuticals | 1.93M |
SciSparc | 1.75M |
Aclarion | 49.29K |
MTEM News
- 2 days ago - Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules - GlobeNewsWire
- 19 days ago - Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements - GlobeNewsWire
- 4 months ago - Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update - GlobeNewsWire
- 7 months ago - Molecular Templates, Inc. Provides Interim Update - GlobeNewsWire
- 7 months ago - Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update - GlobeNewsWire
- 9 months ago - Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patie - GlobeNewsWire
- 9 months ago - Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update - GlobeNewsWire
- 9 months ago - Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement - GlobeNewsWire